Allena Pharmaceuticals
ALNA
ALNA was delisted on the 7th of September, 2022.
35 hedge funds and large institutions have $59.8M invested in Allena Pharmaceuticals in 2019 Q3 according to their latest regulatory filings, with 4 funds opening new positions, 12 increasing their positions, 11 reducing their positions, and 15 closing their positions.
9% more repeat investments, than reductions
Existing positions increased: 12 | Existing positions reduced: 11
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
4% less capital invested
Capital invested by funds: $62.4M → $59.8M (-$2.63M)
24% less funds holding
Funds holding: 46 → 35 (-11)
73% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 15
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
+$784K |
| 2 |
Millennium Management
New York
|
+$682K |
| 3 |
Renaissance Technologies
New York
|
+$215K |
| 4 |
BlackRock
New York
|
+$165K |
| 5 |
LI
LVZ Inc
Holland,
Michigan
|
+$71.8K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PHS
PFM Health Sciences
San Francisco,
California
|
-$1.3M |
| 2 |
Northern Trust
Chicago,
Illinois
|
-$396K |
| 3 |
Morgan Stanley
New York
|
-$200K |
| 4 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
-$169K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
-$153K |
ALNA Hedge Fund Activity: Q3 2019 in Review
35 of the 4,560 institutional investors tracked by Wall St. Rank reported a position in Allena Pharmaceuticals (ALNA) for Q3 2019, worth a combined $59.8M — down 4.2% from $62.4M a quarter earlier.
Sellers outnumbered buyers: 15 funds closed out of ALNA and 4 opened new positions — a net loss of 11 holders — while 11 trimmed existing stakes and 12 added.
The largest buyer was Sphera Funds Management, adding an estimated $784K. The largest seller was PFM Health Sciences, cutting an estimated $1.3M.
- 35 institutional investors held Allena Pharmaceuticals (ALNA) as of Q3 2019, down from 46 in Q2 2019.
- Funds reported $59.8M of Allena Pharmaceuticals stock for Q3 2019, down 4.2% quarter-over-quarter.
- 4 funds opened new Allena Pharmaceuticals positions in Q3 2019 and 15 closed out, a net change of -11 holders.
- The largest Allena Pharmaceuticals buyer in Q3 2019 was Sphera Funds Management, an estimated $784K added.
- The largest Allena Pharmaceuticals seller in Q3 2019 was PFM Health Sciences, an estimated $1.3M sold.
Based on aggregated 13F filings for Q3 2019.